Literature DB >> 22593804

Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer.

Jing Zhao1, Kiera Rycaj, Shanshan Geng, Ming Li, Joshua B Plummer, Bingnan Yin, Hong Liu, Xu Xu, Yinchun Zhang, Yanfang Yan, Sharon A Glynn, Tiffany H Dorsey, Stefan Ambs, Gary L Johanning, Lin Gu, Feng Wang-Johanning.   

Abstract

We previously observed that the HERV type K (HERV-K) envelope (env) protein was expressed in the majority of human breast tumors from a U.S. cohort of women from Texas. We also made the preliminary observation that the expression of HERV-K env transcripts was associated with markers of disease progression. In this follow-up study, env protein expression was evaluated immunohistochemically in an additional 195 paraffin-embedded breast tumors from a second U.S. patient cohort (Baltimore, Maryland) and in 110 tumors from Chinese patients. Moreover, we compared env transcript expression between fresh-frozen normal and cancerous breast tissues. We observed that while env mRNA and protein expression was undetectable in normal breast tissue and in a subset of uninvolved normal-appearing tissue adjacent to the tumor epithelium, it was overexpressed in most tumors. Furthermore, env expression was associated with breast cancer progression. In Baltimore cohort women, HERV-K tumor positivity was significantly associated with disease stage and lymph node metastasis. In Chinese women, HERV-K env positivity was significantly associated with tumor size, TNM stage, and lymph node metastases, which is consistent with the observations in the U.S. cohort. We also found that Chinese breast cancer patients with a high expression of HERV-K had a decreased overall survival compared with patients who had either a moderate or low HERV-K expression in their tumors (P = 0.049, χ(2) log rank test). In conclusion, the HERV-K env gene is expressed in the majority of breast cancers from U.S. or Chinese women but not in normal breast tissue. High expression of HERV-K env protein in breast cancer patients is associated with markers of disease progression and poor disease outcome, indicating that HERV-K env protein is a novel candidate prognostic marker for breast cancer.

Entities:  

Keywords:  breast cancer; envelope (env) protein; human endogenous retrovirus K (HERV-K); prognosis; survival

Year:  2011        PMID: 22593804      PMCID: PMC3352153          DOI: 10.1177/1947601911431841

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  22 in total

1.  An almost-intact human endogenous retrovirus K on human chromosome 7.

Authors:  J Mayer; M Sauter; A Rácz; D Scherer; N Mueller-Lantzsch; E Meese
Journal:  Nat Genet       Date:  1999-03       Impact factor: 38.330

Review 2.  Human endogenous proviruses.

Authors:  E Larsson; N Kato; M Cohen
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

3.  Type 1 HERV-K genome is spliced into subgenomic transcripts in the human breast tumor cell line T47D.

Authors:  P R Etkind; K Lumb; J Du; J Racevskis
Journal:  Virology       Date:  1997-08-04       Impact factor: 3.616

4.  Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.

Authors:  Feng Wang-Johanning; Jinsong Liu; Kiera Rycaj; Miao Huang; Kate Tsai; Daniel G Rosen; Dung-Tsa Chen; Danielle W Lu; Kirstin F Barnhart; Gary L Johanning
Journal:  Int J Cancer       Date:  2007-01-01       Impact factor: 7.396

5.  Nucleotide sequence of human endogenous retrovirus genome related to the mouse mammary tumor virus genome.

Authors:  M Ono; T Yasunaga; T Miyata; H Ushikubo
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

6.  Insertional polymorphisms of endogenous HERV-K113 and HERV-K115 retroviruses in breast cancer patients and age-matched controls.

Authors:  Thomas Burmeister; Andreas D Ebert; Wolfgang Pritze; Christoph Loddenkemper; Stefan Schwartz; Eckhard Thiel
Journal:  AIDS Res Hum Retroviruses       Date:  2004-11       Impact factor: 2.205

7.  Inflammation and IGF-I activate the Akt pathway in breast cancer.

Authors:  Robyn L Prueitt; Brenda J Boersma; Tiffany M Howe; Julie E Goodman; Douglas D Thomas; Lei Ying; Candice M Pfiester; Harris G Yfantis; John R Cottrell; Dong H Lee; Alan T Remaley; Lorne J Hofseth; David A Wink; Stefan Ambs
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

Review 8.  Viruses and human breast cancer.

Authors:  James S Lawson; Walter H Günzburg; Noel J Whitaker
Journal:  Future Microbiol       Date:  2006-06       Impact factor: 3.165

9.  Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker.

Authors:  Maya Golan; Amnon Hizi; James H Resau; Neora Yaal-Hahoshen; Hadar Reichman; Iafa Keydar; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

10.  The search for infectious causes of human cancers: where and why.

Authors:  Harald Zur Hausen
Journal:  Virology       Date:  2009-09-15       Impact factor: 3.616

View more
  38 in total

1.  HIV-1 Infection of Primary CD4+ T Cells Regulates the Expression of Specific Human Endogenous Retrovirus HERV-K (HML-2) Elements.

Authors:  George R Young; Sandra N Terry; Lara Manganaro; Alvaro Cuesta-Dominguez; Gintaras Deikus; Dabeiba Bernal-Rubio; Laura Campisi; Ana Fernandez-Sesma; Robert Sebra; Viviana Simon; Lubbertus C F Mulder
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

2.  Mechanisms of HERV-K (HML-2) Transcription during Human Mammary Epithelial Cell Transformation.

Authors:  Meagan Montesion; Neeru Bhardwaj; Zachary H Williams; Charlotte Kuperwasser; John M Coffin
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

3.  Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells.

Authors:  Fuling Zhou; Ming Li; Yongchang Wei; Kevin Lin; Yue Lu; Jianjun Shen; Gary L Johanning; Feng Wang-Johanning
Journal:  Oncotarget       Date:  2016-12-20

Review 4.  Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.

Authors:  Wenxue Li; Darshan Pandya; Nicholas Pasternack; Marta Garcia-Montojo; Lisa Henderson; Christine A Kozak; Avindra Nath
Journal:  Neurotherapeutics       Date:  2022-04-12       Impact factor: 6.088

5.  Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras.

Authors:  Fuling Zhou; Janani Krishnamurthy; Yongchang Wei; Ming Li; Kelly Hunt; Gary L Johanning; Laurence Jn Cooper; Feng Wang-Johanning
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

6.  Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth.

Authors:  Ming Li; Laszlo Radvanyi; Bingnan Yin; Kiera Rycaj; Jia Li; Raghavender Chivukula; Kevin Lin; Yue Lu; JianJun Shen; David Z Chang; Donghui Li; Gary L Johanning; Feng Wang-Johanning
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

Review 7.  Ancient Adversary - HERV-K (HML-2) in Cancer.

Authors:  Eoin Dervan; Dibyangana D Bhattacharyya; Jake D McAuliffe; Faizan H Khan; Sharon A Glynn
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

8.  Close to the Bedside: A Systematic Review of Endogenous Retroviruses and Their Impact in Oncology.

Authors:  David F Grabski; Yinin Hu; Monika Sharma; Sara K Rasmussen
Journal:  J Surg Res       Date:  2019-03-29       Impact factor: 2.417

9.  Identification of diverse full-length endogenous betaretroviruses in megabats and microbats.

Authors:  Joshua A Hayward; Mary Tachedjian; Jie Cui; Hume Field; Edward C Holmes; Lin-Fa Wang; Gilda Tachedjian
Journal:  Retrovirology       Date:  2013-03-27       Impact factor: 4.602

Review 10.  Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors.

Authors:  Elena Cherkasova; Quinn Weisman; Richard W Childs
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.